Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Payables (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Payables for 8 consecutive years, with $12.8 million as the latest value for Q1 2026.

  • For Q1 2026, Payables rose 25.1% year-over-year to $12.8 million; the TTM value through Mar 2026 reached $12.8 million, up 25.1%, while the annual FY2025 figure was $4.0 million, 32.96% down from the prior year.
  • Payables hit $12.8 million in Q1 2026 for Kymera Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Payables topped out at $12.8 million in Q1 2026 and bottomed at $2.4 million in Q2 2022.
  • Average Payables over 5 years is $6.0 million, with a median of $6.0 million recorded in 2024.
  • Year-over-year, Payables plummeted 70.97% in 2022 and then surged 152.55% in 2023.
  • Kymera Therapeutics' Payables stood at $4.3 million in 2022, then soared by 63.21% to $7.1 million in 2023, then fell by 15.35% to $6.0 million in 2024, then crashed by 32.96% to $4.0 million in 2025, then soared by 219.78% to $12.8 million in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $12.8 million, $4.0 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.